Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Head of Research & Development | June 07, 2021 | June 09, 2021 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 22, 2019 | May 23, 2019 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director · President and CEO | April 02, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date June 07, 2021 · Filed June 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,169.1121 |
Reported balance
After 2021-06-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-07 · Sale · Disposed 7,672 · Balance 10,169.1121 F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2: Includes 102.902 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021.
NEUROCRINE BIOSCIENCES INC
Report date May 22, 2019 · Filed May 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.79 · Expires 2029-05-22 | Direct | 10,000 |
Reported balance
After 2019-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-22 · Grant · Acquired 10,000 · Balance 10,000 F1: Option vests in 12 equal monthly installments beginning June 22, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 12 equal monthly installments beginning June 22, 2019.
Voyager Therapeutics, Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 472,549 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Sale · Disposed 11,511 · Balance 472,549 F1: Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2026. The sales do not represent a discretionary trade by the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.81 to $3.95, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 12, 2020 Filed Feb 14, 2020 23:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 538 | $331.76 | $178,486.88 |
DisclosureSEC source: 0001127602-20-005770 · form4.xml · nonDerivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,926.2451 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,422 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005770 · form4.xml · nonDerivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,464.2451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 660 | $331.76 | $218,961.60 |
DisclosureSEC source: 0001127602-20-005770 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,042.2451 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005770 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,702.2451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 82.051 shares acquired under the Biogen Inc. employee stock purchase plan on March 29, 2019. Read SEC document |
| May 22, 2019 Filed May 23, 2019 21:46 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 10,000 | $0.00 Strike: $79.79 | $0.00 |
DisclosureSEC source: 0001209191-19-032402 · doc4.xml · derivative · entry 1 Sandrock Alfred · CIK 0001577061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2019. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 819 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 819 shares Expires 2019-02-22 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,663 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · derivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819 Underlying: Common Stock · 1,663 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 739 | $325.33 | $240,418.87 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,409.1941 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:07 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-008414 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,148.1941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:08 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 808 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007261 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,128 Underlying: Common Stock · 808 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,318 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007261 · form4.xml · derivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,936 Underlying: Common Stock · 1,318 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 586 | $332.87 | $195,061.82 |
DisclosureSEC source: 0001127602-19-007261 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,485.1941 Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 23:08 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,318 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-007261 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,071.1941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,188 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · derivative · entry 13 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,528 Underlying: Common Stock · 1,188 shares Expires 2021-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,574 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · derivative · entry 12 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,716 Underlying: Common Stock · 1,574 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,453 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · derivative · entry 11 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,453 shares Expires 2019-02-12 F5 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,965 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · derivative · entry 10 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,453 Underlying: Common Stock · 1,965 shares Expires 2019-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,104 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · derivative · entry 9 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,211 Underlying: Common Stock · 1,104 shares Expires 2020-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,330 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · derivative · entry 8 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,330 Underlying: Common Stock · 10,330 shares Expires 2022-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 699 | $319.43 | $223,281.57 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 7 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,753.1941 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 6 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,452.1941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 873 | $319.43 | $278,862.39 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 5 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,878.1941 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,751.1941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 588 | $319.43 | $187,824.84 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,786.1941 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 358 | $319.43 | $114,355.94 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,374.1941 Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:29 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-006099 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,732.1941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 74.812 shares acquired under the Biogen Inc. employee stock purchase plan on 3/29/2018. Read SEC document |
| May 24, 2018 Filed May 26, 2018 00:04 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantNon-Qualified Stock Option · Derivative | 12,500 | $0.00 Strike: $94.64 | $0.00 |
DisclosureSEC source: 0001209191-18-033638 · doc4.xml · derivative · entry 1 Sandrock Alfred · CIK 0001577061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-24 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 24, 2018. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 22:39 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 259 | $290.83 | $75,324.97 |
DisclosureSEC source: 0001127602-18-009190 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,553.3821 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:25 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 595 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008815 · form4.xml · derivative · entry 5 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 595 shares Expires 2018-02-23 F5 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 467 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008815 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595 Underlying: Common Stock · 467 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 208 | $292.78 | $60,898.24 |
DisclosureSEC source: 0001127602-18-008815 · form4.xml · nonDerivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,812.3821 Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 467 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008815 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,020.3821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 23:25 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 908 | $293.44 | $266,443.52 |
DisclosureSEC source: 0001127602-18-008815 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,553.3821 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer. F3 · price: This represents the weighted average price for shares sold at a range between $293.30 (low) and $294.00 (high). Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 843 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008406 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,482 Underlying: Common Stock · 843 shares Expires 2019-02-22 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,635 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008406 · form4.xml · derivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,325 Underlying: Common Stock · 1,635 shares Expires 2019-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 727 | $284.81 | $207,056.87 |
DisclosureSEC source: 0001127602-18-008406 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,461.3821 Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 21:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,635 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-008406 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,188.3821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2018 Filed Feb 21, 2018 21:10 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 743 | $292.00 | $216,956.00 |
DisclosureSEC source: 0001127602-18-007526 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,553.3821 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 15, 2018 Filed Feb 21, 2018 01:09 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 1,294 | $298.85 | $386,711.90 |
DisclosureSEC source: 0001127602-18-007393 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,296.3821 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:25 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 787 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007209 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,254 Underlying: Common Stock · 787 shares Expires 2020-02-15 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,339 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007209 · form4.xml · derivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,041 Underlying: Common Stock · 1,339 shares Expires 2020-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 596 | $299.38 | $178,430.48 |
DisclosureSEC source: 0001127602-18-007209 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,590.3821 Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 21:25 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-007209 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,186.3821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,398 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006179 · form4.xml · derivative · entry 7 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,418 Underlying: Common Stock · 1,398 shares Expires 2019-02-12 F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 2,012 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006179 · form4.xml · derivative · entry 6 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,816 Underlying: Common Stock · 2,012 shares Expires 2019-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest each year for four years, beginning two years from the date of grant. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 8,290 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006179 · form4.xml · derivative · entry 5 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,290 Underlying: Common Stock · 8,290 shares Expires 2021-02-12 F3 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 3,315 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006179 · form4.xml · derivative · entry 4 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,315 Underlying: Common Stock · 3,315 shares Expires 2020-02-12 F2 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 718 | $316.63 | $227,340.34 |
DisclosureSEC source: 0001127602-18-006179 · form4.xml · nonDerivative · entry 3 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,847.3821 Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 2,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-006179 · form4.xml · nonDerivative · entry 2 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,565.3821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 23:37 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 598 | $316.63 | $189,344.74 |
DisclosureSEC source: 0001127602-18-006179 · form4.xml · nonDerivative · entry 1 Sandrock Alfred · CIK 0001577061 · EVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,553.3821 F1 · balance_after: Includes 91.527 shares acquired under the Biogen Inc. Employee Stock Purchase Plan on 3/31/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.